Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: A potential therapeutic approach for Sanfilippo disease

European Journal of Human Genetics

Volumn 18, Issue 2, 2010, Pages 200-205

  Dziedzic, Dariusz ^a   Wgrzyn, Grzegorz ^a   Jakóbkiewicz Banecka, Joanna ^a  

^a UNIVERSITY OF GDA SK   (Poland)

Author keywords

Interference RNA; Sanfilippo disease; SiRNA

Indexed keywords

BETA 1,3 GALACTOSYLTRANSFERASE 6; BETA 1,4 GALACTOSYLTRANSFERASE 7; BETA DEXTRO XYLOSYLTRANSFERASE I; BETA DEXTRO XYLOSYLTRANSFERASE II; GLYCOSAMINOGLYCAN; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME SUBSTRATE; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GLYCOSAMINOGLYCAN METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; SANFILIPPO SYNDROME;

EID: 74649083006     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2009.144     Document Type: Article

References (32)

1. Neufeld EF, Muenzer J: The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill Co, 2001. pp 3421-3452.
2. Heese BA: Current strategies in the management of lysosomal storage diseases. Semin Pediatr Neurol 2008; 15: 119-126.
3. Piotrowska E, Jakóbkiewicz-Banecka J, Barań ska S et al: Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 2006; 14: 846-852.
4. Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S: Inhibition of glycosa-minoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr Res 2006; 60: 309-314.
5. Roberts AL, Rees MH, Klebe S, Fletcher JM, Byers S: Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab 2007; 92: 115-121.
6. Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymańska A et al: Genistin-rich iso-flavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients. Curr Ther Res Clin Exp 2008; 69: 166-179.
7. Jakóbkiewicz-Banecka A, We?grzyn A, We?grzyn G: Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J Appl Genet 2007; 48: 383-388.
8. Karstens T, Kobs K: Rhodamine B and rhodamine 101 as reference substances for fluorescence quantum yield measurements. J Phys Chem 1980; 84: 1871-1872.
9. Szkudelska K, Nogowski L: Genistein-a dietary compound inducing hormonal and metabolic changes. J Steroid Biochem Mol Biol 2007; 105: 37-45.
10. Kim D, Rossi J: RNAi mechanisms and applications. Biotechniques 2008; 44: 613-616.
11. Shen Y: Advances in the development of siRNA-based therapeutics for cancer. Idrug 2008; 11: 572-578.
12. Juliano R, Alam MR, Dixit V, Kang H: Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008; 36: 4158-4171.
13. Prydz K, Dalen K: Synthesis and sorting of proteoglycans. J Cell Sci 2000; 113: 193-205.
14. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Method 2001; 25: 402-408.
15. Smith RA, Miller TM, Yamanaka K et al: Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006; 116: 2290-2296.
16. Kaidonis X, Liaw WC, Roberts AD, Ly M, Anson D, Byers S: Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing muco-polysaccharidoses. Eur J Hum Genet 2009, E-pub ahead of print; doi:10.1038/ ejhg.2009.143.
17. Lin X, Wei G, Shi Z et al: Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev Biol 2000; 224: 299-311.
18. Zak BM, Crawford BE, Esko JD: Hereditary multiple exostoses and heparan sulfate polymerization. Biochim Biophys Acta 2002; 1573: 346-355.
19. Forsberg E, Kjellen L: Heparan sulfate: lessons from knockout mice. J Clin Invest 2001; 108: 175-180.
20. Ringvall M, Ledin J, Holmborn K et al: Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N- sulfotransferase-1. J Biol Chem 2000; 275: 25926-25930.
21. Forsberg E, Pejler G, Ringvall M et al: Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 1999; 400: 773-776.
22. Grobe K, Inatani M, Pallerla SR, Castagnola J, Yamaguchi Y, Esko JD: Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development 2005; 132: 3777-3786.
23. Merry CL, Bullock SL, Swan DC et al: The molecular phenotype of heparan sulfate in the Hs2st-/-mutant mouse. J Biol Chem 2001; 276: 35429-35434.
24. Wilson VA, Gallagher JT, Merry CL: Heparan sulfate 2-O-sulfotransferase (Hs2st) and mouse development. Glycoconj J 2002; 19: 347-354.
25. Merry CL, Wilson VA: Role of heparan sulfate-2-O-sulfotransferase in the mouse. Biochim Biophys Acta 2002; 1573: 319-327.
26. Shworak NW, HajMohammadi S, de Agostini AI, Rosenberg RD: Mice deficient in heparan sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes. Glycoconj J 2002; 19: 355-361.
27. Habuchi H, Nagai N, Sugaya N, Atsumi F, Stevens RL, Kimata K: Mice deficient in heparan sulfate 6-O-sulfotransferase-1 exhibit defective heparan sulfate biosynthesis, abnormal placentation, and late embryonic lethality. J Biol Chem 2007; 282: 15578-15588.
28. Li JP, Gong F, Hagner-McWhirter A et al: Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate lacking L-iduronic acid and in neonatal lethality. J Biol Chem 2003; 278: 28363-28366.
29. Hickerson RP, Vlassov AV, Wang Q et al: Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 2008; 18: 345-354.
30. Sioud M, Sørensen DR: Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 2003; 312: 1220-1225. (Pubitemid 37490947)
31. Song E, Lee SK, Wang J et al: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-351.
32. Jakóbkiewicz-Banecka J, Piotrowska E, Narajczyk M, Barańska S, Wegrzyn G: Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 2009; 16: 26.